e-ISSN: 0975-5160, p-ISSN: 2820-2651

Available online on www.ijtpr.com

International Journal of Toxicological and Pharmacological Research 2023; 13(6); 280-284

Original Research Article

Present Scenario in Pharma Research and Business Management

Avani Reddy Alla[1], Kevin T Cherian[2], Ramya Surapaneni[3], Vijay Kumar Gajula[4], Srikanth Sangoju[5], Jyothi Sabbani[6], Prathyusha Bandari[7], Sunil Kumar Adepu[8]

[1]MBBS, MS in Business Analytics, Senior Statistical Programmer.
[2]M.D (General Medicine).
[3]M.Pharm (Quality Assurance).
[4]M.Pharm (Pharma Sales & Marketing).
[5]MBA, (Pharma Sales & Marketing).
[6]M.Sc. Chemistry (Quality Control).
[7]M. Sc. Biotech (Medical Coding).
[8]Student of Doctor of Healthcare Management, The Masterminds International University, Kingdom Of Eswatini (Swaziland), Africa.

Received: 22-04-2023 / Revised: 25-05-2023 / Accepted: 27-06-2023
Corresponding author: Sunil Kumar Adepu
Conflict of interest: Nil

Abstract

The Indian pharmaceutical industry truly came into its own after gaining independence. Today, it stands as the fourth largest market for generic pharmaceuticals globally. In terms of volume, it ranks fourth, while in terms of value, it holds the thirteenth position among global pharmaceutical markets. Furthermore, the industry demonstrates consistent growth.

To uphold the quality, safety, and effectiveness of medicinal products for sales, imports, and manufacturing, a robust regulatory system is in place. The regulatory framework governing India's pharmaceutical industry is among the most stringent in the country. Given the rapid and continuous changes in this field, it is crucial to comprehend the regulatory landscape. Regulatory bodies bear the responsibility of ensuring a steady supply of high-quality medications at affordable prices to the Indian population, which places a significant burden on them.

Keywords: Pharmaceutical industry, Regulatory bodies, CDSCO.

Introduction

In this context, regulatory agencies and organizations worldwide play a crucial role in ensuring the safety, quality, and efficacy of medicines and medical devices. They also focus on harmonizing legal procedures related to drug development, monitoring, and enforcing compliance with statutory obligations. The primary challenge faced by these regulatory bodies is to promote public health and safeguard individuals from potentially harmful or questionable drugs.[1]

The Regulatory Affairs department holds a crucial position within the organizational structure of pharmaceutical companies. Internally, it serves as a liaison, bridging the various stages of drug development, manufacturing, marketing, and clinical research. Externally, it plays a vital role as the primary interface between the company and regulatory authorities. By

fulfilling these responsibilities, the Regulatory Affairs department plays a pivotal role in upholding compliance and facilitating effective communication between the company and regulatory bodies.[2]

Regulatory Bodies

Country	Regulatory Authority
US	Food and Drug Administration (US FDA)
UK	Medicines and Health care products regulatory Agency (MHRA)
India	Central Drugs Standard Control Organization Drug controller general of India (DCGI)
Australia	Therapeutic Goods Administration (TGA)
Japan	Japanese Ministry of health, Labour and Welfare (MHLW)
Canada	Health Canada
Brazil	Agency Nacional degradation Vigilancia Sanitaria (ANVISA)
South Africa	Medicines Control Council (MCC)
Europe	European Directorate for Quality of Medicines (EDQM)
	European Medicines Evaluation agencies (EMEA)

Figure 1: International Regulatory Bodies (Source: self)



Figure 2: Indian Regulatory Bodies (Source: self)

The Central Drug Standards and Control Organization (CDSCO) operates as the primary regulatory body responsible for overseeing the manufacturing, drug development, and marketing approval processes for high-quality drugs in India. Under the Ministry of Health and Family

Welfare, the CDSCO plays a pivotal role in establishing standards and implementing measures to ensure the safety, efficacy, and quality of drugs, cosmetics, diagnostics, and devices within the country.[3]

The CDSCO's responsibilities encompass a wide range of activities. It plays a crucial role in granting market authorization for new drugs, setting standards for clinical trials, supervising the importation of drugs, and issuing licenses for manufacturing products. This organization acts as a key authority in safeguarding public health by ensuring the adherence to stringent regulations and guidelines throughout the pharmaceutical industry.

At the state level, the state drug regulatory authority collaborates with the CDSCO. These state-level authorities are responsible for issuing licenses to manufacture approved drugs and monitoring the quality of drugs within their respective regions. Together with the CDSCO, they work in tandem to maintain strict regulatory oversight and uphold the integrity of the pharmaceutical sector.[4]

Function of Regulatory Authority[5]

Pharmaceutical regulatory authorities play a crucial role in ensuring the safety, efficacy, and quality of pharmaceutical products. Their primary functions include:

- Approval and Market Authorization
- Regulation and Compliance
- Clinical Trials Oversight
- Pharmacovigilance and Adverse Event Reporting
- Quality Control and Inspections
- Pricing and Reimbursement
- International Collaboration and Harmonization.

The Present Scenario

The pharmaceutical industry is continuously evolving and adapting to various factors in the present scenario The pandemic has had a profound impact on the pharmaceutical industry. Pharmaceutical companies worldwide have been engaged in developingCOVID-19 vaccines, therapeutics, and diagnostics to combat the virus. Efforts are being made to increase vaccine production, address supply chain issues, and ensure fair distribution across countries, especially to low- and middle-income nations.The pharmaceutical industry is embracing digital technologies and innovations to enhance research and development, clinical trials, manufacturing processes, and supply chain management. Artificial intelligence (AI), machine learning, big data analytics, and telemedicine are being utilized to improve efficiency, drug discovery, personalized medicine, and patient care. Biotechnology and gene therapy continue to make significant advancements in the pharmaceutical field. Cutting-edge therapies, such as gene editing, cell-based immunotherapies, and RNA-based therapeutics, are being developed to address previously untreatable diseases and conditions. Regulatory bodies continue to refine and adapt regulations to ensure patient safety, efficacy, and quality of pharmaceutical products. There is a growing focus on expedited review processes, real-world evidence, and post-marketing surveillance to monitor drug safety and effectiveness. Healthcare costs, including pharmaceutical expenses, remain a concern globally. Efforts are being made to address pricing transparency, value-based pricing, and access issues to ensure affordable and accessible medicines for patients. The pharmaceutical industry is increasingly focusing on sustainability practices and reducing its environmental footprint. This includes efforts to minimize waste, optimize energy consumption, and adopt eco-friendly manufacturing processes. Collaboration between pharmaceutical companies, research institutions, and governments is crucial for drug

development, innovation, and addressing global health challenges. Public-private partnerships are being formed to accelerate research, improve access to medicines, and tackle diseases like neglected tropical diseases and antimicrobial resistance.[6-7]

The Revenue generated by the Pharmaceutical companies all over the world has been increasing. In India, the export of drugs is one of the major sources of revenue generation for the pharma industry. The Indian pharma industries are generating almost 55% of their total revenue from exports. The pharmaceutical industry is mainly divided into two segments i.e. API (Active Pharmaceutical Ingredients), Formulations and other pharmaceuticals. The export percentage of formulation drugs has increased over the past few years.[8-9]



Figure 3: Pharmaceutical market worldwide revenue (Source: Statista 2017)



Figure 4: Indian Pharmaceuticals Industry Analysis: (Source:IBEF 2018)

India is known as the "pharmacy of the world" due to its robust generic pharmaceutical manufacturing capabilities. The industry has been instrumental in providing affordable medicines globally, especially in developing countries. The Indian pharmaceutical industry is the fourth largest in the world in terms of volume and thirteenth largest in terms of value. It contributes a significant share to the global pharmaceutical market, with a focus on the production of generic drugs.

Conclusion

The pharmaceutical industry stands as the largest industry worldwide. In recent years, this industry has experienced significant transformations, which bring forth new challenges for payers, providers, and manufacturers alike. To navigate these changes successfully, life-science companies rely on their Regulatory Affairs departments, ensuring adherence to all regulations and laws governing their operations.

References

1. Milind S, Sandeep J, Chirag S, Venkata PP. Pharmaceutical Research in India: Current Status and Opportunities. Proc Indian Natn Sci Acad. 2020; 86(2): 1015-1022.
2. Shaik SB, Shakeel SM., Nagabhushanam MV, Nagarjuna R, Brahmaiah B. The Assessment of Current Regulatory Guidelines for Biosimilars- A Global Scenario. World Journal of Pharmaceutical Research. 2016; (6): 351-369.
3. Kataria BC, Panchal PJ, Panchasara AK, Pandya AS, Parmar MR. Comparison of new drug approval by regulatory agencies of US, EU and India. International Journal of basic and clinical pharmacology. 2016; 51.
4. De Meyer A, Nakane J, Miller, JM, Ferdows K. Flexibility: The next competitive battle: the manufacturing futures survey. Strategic Management Journal. 1989; 10(2): 135–144.
5. Ikeda K, Takeoka S. Evaluation of Recently Discontinued Drugs to Identify Factors Contributing to their Failure and to Improve the Efficiency of Pharmaceutical Drug Development. J Clin Med Ther. 2018; 31:4.
6. Babler S. Pharmaceutical and biomedical project management in a challenging global environment. Hoboken, NJ: John Wiley & Sons, Inc. 2010.
7. Kaplan RS, Norton DP. Using the balanced scorecard as a strategic management system. Harvard Business Review. 2007; 74(1): 75–85.
8. Statista. Pharmaceutical market worldwide revenue 2001-2016 Statistic. 2017.
9. IBEF. Indian Pharmaceuticals Industry Analysis: A Sectoral Presentation. 2018.